Navigation Links
China Biopharma, Inc. Issues Corporate Information Update
Date:12/26/2008

HANGZHOU, China, Dec. 26 /PRNewswire/ -- China Biopharma, Inc. (OTC Bulletin Board: CHBO) issued corporate information updates today.

The Company had significant operational improvement after the start of corporate operational restructuring last year. For the nine months ended September 30, 2008, it has made approximately $5.4 million in sales, more than thirteen times the sales revenue made in the same period of 2007, which was approximately $0.4 million. It also made approximately $90,000 in net profit from the China operation, comparing to a net loss of approximately $0.35 million in the same period of 2007. The Company believes that the current operation will further improve as it finalizes the operational restructuring.

The Company has signed an agreement with Zhejiang Tianyuan Biopharma Co., Ltd. that the Company will increase its stakes from currently 65% to 100% in the joint venture, Zhejiang Tianyuan Biotech Co., Ltd. ("ZTBC"). ZTBC will become a wholly owned subsidiary of the Company, and will change its name to Zhejiang Kangchen Biotech Co., Ltd. It is waiting for the new business license.

The Company has signed an agreement to acquire 90% of Beijing Tiancheng Xinhai Pharmaceutical Co., Ltd. ("BTXP"), a regional pharmaceutical distribution company. The company now has full operating control in BTXP and is waiting for final governmental approval and new business license.

After completion of recent operational restructuring, the company is looking for future merge and acquisitions. The Company is projecting a 25% sales increase in 2009.

About China Biopharma, Inc.

China Biopharma, Inc. is a pharmaceutical company based in China. Through its operating subsidiaries, the company introduces and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include biopharmaceutical and other pharmaceutical drugs. Leveraging its local presence and the relationship with local Chinese pharmaceutical companies and international pharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as in new world markets, including the U.S. and Europe. For more information, visit its website at HYPERLINK "http://www.chinabiopharma.net/"http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

    CONTACT:

    China Biopharma, Inc.
    Tel: +1 (609) 651-8588
    ir@chinabiopharma.net
   http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watching water from space could aid disease prevention in China
2. China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
3. Chinas Views on Mental Disorders Improving but Challenges Remain
4. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
5. China Shenghuo to Resume Trading on NYSE Alternext US LLC
6. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
7. China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs
8. Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources Private Sourcing Events
9. Diagnosis and Drug Treatment of Alzheimers Disease in China is Low and Will Remain Low Through 2012
10. China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO
11. Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products : Government and Industry Increase Contaminant Testing to Increase Food Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Cambridge, MA (PRWEB) , ... July 24, 2017 , ... ... for an invigorating and educational conference, InstructureCon. Each annual event is coupled with a ... next level with a James Bond theme, Mission: InstructureCon 0017. , To extend ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology: